Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

- Loo, Sun, Roberts, Andrew W., Taper, John, Cull, Gavin, Tiley, Campbell, Verner, Emma, Hahn, Uwe, Hiwase, Devendra K., Iland, Harry J., Murphy, Nick, Ramanathan, Sundra, Reynolds, John, Anstee, Natasha S., Ong, DM, Tiong, IS, Wall, M, Murray, M, Rawling, T, Leadbetter, J, Rowley, L, Latimer, M, Yuen, SLS, Ting, SB, Kennedy, Glen A., Fong, CY, Morris, KL, Bajel, A, Seymour, JF, Levis, MJ, Wei, AH, He, Simon, Schwarer, Anthony P., Enjeti, Anoop K., D'Rozario, James, Marlton, Paula, Bilmon, Ian A.

Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation

- Joshi, Maansi, Taper, John, Huang, Gillian, Hertzberg, Mark, Forsyth, Cecily, Rowlings, Philip, Campbell, Philip, Crispin, Philip, Harvey, Michael, Underhill, Craig, Bayley, Angela, Byth, Karen

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

- Iland, Harry J., Collins, Marnie, Hugman, Amanda, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bradstock, Ken, Bashford, John, Seymour, John F., Supple, Shane G., Catalano, Alberto, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Campbell, Lynda J.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

- Iland, Harry J., Bradstock, Ken, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bashford, John, Supple, Shane G., Seymour, John F., Catalano, Alberto, Collins, Marnie, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Hugman, Amanda